Molecular Templates, Inc.: management transactions · United States · SEC (Form 4)

About Molecular Templates, Inc.

Molecular Templates, Inc. (ticker: MTEM) is a United States biopharmaceutical company listed on the Nasdaq market. Historically headquartered in Austin, Texas, the company was formed in 2001 and built its strategy around a proprietary biologic platform known as Engineered Toxin Bodies (ETBs). The core scientific concept was to create targeted biologic therapeutics with potent mechanisms of action designed to attack diseased cells while limiting off-target exposure, primarily in oncology and other serious diseases. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1183765/000156459023004898/mtem-10k_20221231.htm?utm_source=openai)) From a business model perspective, Molecular Templates has been a classic clinical-stage biotechnology company: highly research-intensive, pre-commercial, and dependent on scientific milestones, capital access, and partnership optionality. The company has highlighted several development programs over time, including MT-6402, MT-5111, MT-0169, and earlier work on MT-8421. In 2024, management reported clinical data for MT-6402 at AACR and described a tolerable safety profile together with signs of efficacy in heavily pretreated head and neck cancer patients, underscoring the platform’s differentiated therapeutic ambition. ([nasdaq.com](https://www.nasdaq.com/press-release/molecular-templates-inc.-reports-first-quarter-2024-financial-results-and-corporate?utm_source=openai)) Competitively, MTEM operated in a crowded and capital-intensive biotech landscape where value creation depends on differentiation, clinical safety and efficacy, intellectual property strength, and the ability to fund long development cycles. The company’s SEC filings emphasized a broad patent estate covering its platform technologies, which is important in a sector where IP protection and mechanistic uniqueness are central to partnering and valuation. Unlike commercial-stage pharma companies, Molecular Templates did not have a diversified revenue base; investor returns were tied to pipeline progress and strategic transactions rather than product sales. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1183765/000156459023004898/mtem-10k_20221231.htm?utm_source=openai)) Geographically, the company’s historic operating footprint was concentrated in the United States, with Austin, Texas as its corporate headquarters and earlier references to office space in Jersey City, New Jersey. The investor-facing information now on the company website states that Molecular Templates is no longer operating, which is highly material for investors following the stock. That means MTEM should be viewed as a legacy Nasdaq-listed biotech shell rather than an active development platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1183765/000156459023004898/mtem-10k_20221231.htm?utm_source=openai)) The most important recent development came in October 2024, when the board approved, subject to stockholder approval, the liquidation and wind-up of the company through a plan of dissolution while still exploring strategic alternatives and funding sources to maximize value. The proxy materials filed later in 2024 continued to focus on the dissolution process. For French-speaking investors, the key takeaway is that MTEM’s profile changed materially in late 2024: instead of being assessed as a live clinical-stage biotech, it now has to be analyzed through the lens of winding down and value realization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1183765/000119312524236770/d840872d8k.htm?utm_source=openai))